Showing posts sorted by date for query BIOPHAGES. Sort by relevance Show all posts
Showing posts sorted by date for query BIOPHAGES. Sort by relevance Show all posts

Tuesday, September 09, 2025

‘Microbial piracy’ uncovers new way to fight drug-resistant infections





Imperial College London






Researchers have discovered how ‘pirate phages’ hijack other viruses to break into bacteria, sharing new genetic material for dangerous traits.

Imperial scientists have uncovered how bacteriophages are able to hijack other viruses to break into bacterial cells and spread, through an act of microbial piracy which could potentially be harnessed for medicine.

The discovery, published in the journal Cell, reveals a major route by which bacteria are able to acquire new genetic material, including traits that can make them more virulent or more resistant to antibiotics. The researchers believe it could also open the door to new ways of tackling the global threat of antimicrobial resistance (AMR) and developing rapid diagnostic tools.

Phages (or bacteriophages) are viruses that infect and kill bacteria. They are among the most abundant organisms on Earth and are often highly specific, each tailored to attack just one bacterial species. Structurally, they resemble microscopic syringes: with a ‘head’ section packed with DNA and a tail section tipped with spiky fibres that latch onto bacteria and inject their genetic payload.

But phages themselves are not safe from parasites. They can be targeted by small genetic elements known as phage satellites that hijack the phage’s own genetic machinery to propagate.

In the latest study, Imperial researchers focused on a powerful family of phage satellites called capsid-forming phage-inducible chromosomal islands (cf-PICIs). These genetic elements can spread genes for antibiotic resistance and virulence, and are found across more than 200 bacterial species. Exactly how they managed to move so efficiently, however, was unclear.

First discovered by the team in 2023, cf-PICIs can build their own capsids (the viral ‘heads’), but they lack tails, meaning on their own they produce non-infective particles – i.e. they are not able to infect phages. In their latest work, researchers at Imperial’s Centre for Bacterial Resistance Biology discovered the missing piece of the puzzle: cf-PICIs hijack tails from unrelated phages, creating hybrid “chimeric” viruses. The result is a chimeric phage carrying cf-PICI DNA inside their own capsids but a phage-derived tail attached.

Crucially, some cf-PICIs can hijack tails from entirely different phage species, effectively broadening their host range. Because the tail decides which bacteria are targeted, this piracy gives cf-PICIs the ability to infiltrate new bacterial species, explaining their great abundance in nature.

According to the researchers, the implications could be important for science. By understanding and harnessing this molecular piracy, researchers believe they could re-engineer satellites to target antibiotic-resistant bacteria, overcome stubborn bacterial defences such as biofilms, and even develop powerful new diagnostic tools.

“These pirate satellites don’t just teach us how bacteria share dangerous traits,” explains Dr Tiago Dias da Costa, from Imperial’s Department of Life Sciences. “They could inspire next-generation therapies and tests to outmanoeuvre some of the most difficult infections we face.”

The Imperial team has successfully filed patents to further develop the work and hopes to begin testing the translational applications of the technology.

Professor Jose Penades, from Imperial’s Department of Infectious Disease, said: “Our early work first identified these odd genetic elements, where we found they are effectively a parasite of a parasite. We now know these mobile genetic elements form capsids which can swap ‘tails’ taken from other phages to get their own DNA into a host cell. It’s an ingenious quirk of evolutionary biology, but it also teaches us more about how genes for antibiotic resistance can be spread through a process called transduction.”

Dr Dias da Costa, added: “This experimental work sheds more light on a crucial method of gene transfer in bacteria. If we can harness and engineer cf-PICIs it could provide us with a valuable new tool in the fight against antimicrobial resistance.”

AI co-scientist tool
In a linked project, coordinated through the Fleming Initiative – a partnership between Imperial College London and Imperial College Healthcare NHS Trust – researchers used their experimental work to validate a groundbreaking AI platform developed by Google.

Dubbed the ‘co-scientist’, the platform is designed to help scientists develop smarter experiments and accelerate discovery.

To test the platform, the Imperial team posed the same basic scientific questions that had driven their own work: How do cf-PICIs spread across so many bacterial species?

Armed with this starting point, and drawing on web searches, research papers, and databases, the AI independently generated hypotheses that mirrored the team’s own experimentally proven ideas – effectively pointing to the same experiments that had taken years of work to establish, but doing so in a matter of days.

The researchers say this shows the extraordinary potential of AI systems to ‘super-charge science’, not by replacing human insight, but by accelerating it. They are now working with Google to further develop the platform and explore how it could transform the pace of biomedical research.

‘Chimeric infective particles expand species boundaries in phage inducible chromosomal island mobilization’ by He L & Patkowski JB, et al. is published in the journal Cell. DOI: 10.1016/j.cell.2025.08.019

‘AI mirrors experimental science to uncover a novel mechanism of gene transfer crucial to bacterial evolution’ by Penades JP et al. is published in the journal Cell. DOI: 10.1016/j.cell.2025.08.018

 

Wednesday, June 04, 2025

 

Phage therapy at a turning point: Global experts converge in Berlin to shape the future of antimicrobial medicine




Mitochondria-Microbiota Task Force
Phage Therapy Agenda 

image: 

Targeting Phage Therapy Agenda

view more 

Credit: International Society of Microbiota





As antibiotic resistance reaches critical levels worldwide, the 8th World Congress on Targeting Phage Therapy (June 10–11, 2025) returns to Berlin, bringing together over 75 international speakers and contributors from 27 countries. The congress offers the most comprehensive scientific and clinical update on phage therapy—a once-overlooked solution now at the forefront of next-generation medicine.

Phage Therapy 2025 covers the full translational pipeline: from phage–bacteria interactions and biofilm disruption to regulatory frameworks, GMP manufacturing, and clinical case studies across human and veterinary medicine.

Highlights from the 2025 Program

  • Keynote Address: “Phage Therapy 2030: Getting from Here to There” by Prof. Robert T. Schooley (University of California San Diego)
  • Breakthrough Clinical Cases: Personalized phage therapy in cystic fibrosis, prosthetic joint infections, and critical MDR cases from Australia, Canada, and Georgia
  • Phages in Oncology: Groundbreaking applications in tumor targeting and immunomodulation from teams in Italy and Slovenia
  • One Health in Action: Presentations from Spain, Poland, and Japan on phage use in livestock, food safety, and veterinary infections
  • Session 5 – From Bench to Market: Regulatory innovation, GMP production pipelines, and commercialization insights from leading European CDMOs and biotech firms

Emerging Themes and Hot Topics in Phage Therapy 2025

Precision Phage Engineering

Researchers are now developing genetically customized phages with enhanced specificity, immune evasion mechanisms, and synthetic delivery modules—ushering in a new era of personalized and programmable therapies.

Phage–Microbiota Interactions

Phages are gaining recognition not only as antimicrobial agents but as key modulators of the gut microbiome, with therapeutic implications in chronic inflammation, metabolic disorders, and immune regulation.

Phage–Antibiotic Synergy

Rather than serving as alternatives, phages and antibiotics are proving to be complementary tools. Several studies demonstrated how phages can re-sensitize resistant bacteria, dismantle biofilms, and extend antibiotic lifespan.

Regulatory & GMP Acceleration

From compassionate use protocols to full GMP production, the congress emphasized rapid progress in aligning legal frameworks, production standards, and clinical accessibility.

Next-Gen Preclinical Models

Innovative models, including the ex vivo pig lung system for cystic fibrosis, are revolutionizing how phage efficacy and safety are validated prior to human use.

Global Harmonization

Speakers emphasized the urgent need for international coordination on phage libraries, production protocols, and regulatory pathways.

Phages Beyond Infections

Talks explored novel uses of phages in cancer immunotherapy, vaccine delivery, and systemic immune modulation.

Driving Innovation: JAFRAL and Cellexus

Two strategic industry leaders showcased the technologies that are making phage therapy commercially viable:

• JAFRAL (Slovenia) is a leading Contract Development and Manufacturing Organization (CDMO) for GMP-grade bacteriophage production. With experience supporting over 12 clinical trials globally, JAFRAL delivers scalable manufacturing solutions for human and veterinary therapeutics, food, and agriculture. JAFRAL’s state-of-the-art manufacturing facilities are equipped to deliver GMP-compliant and non-GMP bacteriophage products with batch capacities of up to 200 liters, fully aligned with FDA, EMA and TGA regulatory standards. The company provides end-to-end services—from process and analytical method development to large-scale production—tailored to meet the stringent demands of both clinical and commercial use. The company offers diverse formulation capabilities, including liquid formulations, spray drying, and lyophilization, ensuring flexible and customized solutions for a wide range of therapeutic and industrial applications.

• Cellexus (United Kingdom) presented the CellMaker system—currently the only single-use, purely airlift bioreactor on the market. Designed for phage and viral production, CellMaker enables scalable, shear-free bioprocessing compliant with GMP standards, bridging the gap between research and industrial application. The CellMaker range of revolutionary, single-use airlift bioreactor systems simplify, accelerate and improve cell culture and fermentation processes with a system expertly designed for the life sciences and pharmaceutical industries.

Concluding Remarks

In closing, Prof. Christian Willy remarked:
“Phage therapy is no longer an experimental tool—it is becoming an essential component of post-antibiotic medicine. What we do now will define its accessibility and legitimacy in clinical care for decades.”

As resistance to conventional antibiotics continues to grow, Targeting Phage Therapy 2025 sends a clear message: the future of infectious disease treatment is not just bacterial—it’s viral.

For More information: www.phagetherapy-site.com

For Press Access, Interview Requests, or Conference Media Kit:

Email: contact@phagetherapy-site.com

Website: www.phagetherapy-site.com


SEE

https://plawiuk.blogspot.com/search?q=PHAGES


Wednesday, May 21, 2025

 

Inhaled microplastics inhibit key immune cell in the lungs



Study also shows how macrophage function can be restored after exposure



American Thoracic Society

Adam Soloff, MD 

image: 

Adam Soloff, PhD, associate professor of cardiothoracic surgery at the University of Pittsburgh and first author of the study.

view more 

Credit: Adam Soloff, MD






Session:  B15—Macrophages: The Pac-Man of the Immune System

Inhaled Microplastics Inhibit Tissue Maintenance Functions of Pulmonary Macrophages

ATS 2025, San Francisco – Microplastics are ubiquitous in the environment, and we all routinely inhale these tiny pollutants. Now new research published at the ATS 2025 International Conference has found that inhaled microplastics suppress pulmonary macrophages, a type of white blood cell found in the lungs that are critical to the immune system.

The findings shed new light on the mechanisms through which microplastic exposure leads to long-term disruption of immune function and increases risk of cancer and other diseases. These risks aren’t limited to the lungs but can affect the entire body.

“For me, it’s a bit eye opening that although microplastics aren’t the most dangerous agent we may encounter, they are far from benign,” said Adam Soloff, PhD, associate professor of cardiothoracic surgery at the University of Pittsburgh and first author of the study. “Respiratory microplastics disseminate systemically after passing through the lung and negatively affect macrophage function. Overall, these may have detrimental effects on any and all organ systems and contribute to a number of diseases.”

Macrophages are the most abundant immune cell of the lung and play a critical role. These cells work as immune housekeepers, devouring pathogens and maintaining tissue homeostasis. They also clear away dead lung cells, which can cause chronic inflammation when they’re left to accumulate.

For the study, researchers cultured macrophages with polystyrene microplastics at different sizes and concentrations. They also exposed mice to inhaled microplastics and then measured the effects on the animals’ macrophage function.

They found that within 24 hours of exposure to microplastics of any size, the macrophages showed a reduced ability to surround and absorb other bacteria, a critical process called phagocytosis. Microplastic particles were readily detected in the liver, spleen and colon with trace amounts in the brain and kidney for up to a week after being inhaled.

Researchers also found that the drug Acadesine, an AMP kinase activator, was able to partially restore macrophage function after microplastic exposures.

Dr. Soloff said the results were surprising.

“When we first started to discuss these microplastic exposures, I was sure that the macrophages would just eat (phagocytose) and digest them (lysosomally process), and that would be the end of it,” he said. “I was really surprised to see that not only did the macrophages struggle to break down the plastics in vitro, but macrophages in the lung retained these particles over time as well.”

In addition to driving public health measures to reduce the use of plastics overall, the findings could support the use of drugs like Acadesine in at-risk populations.

“Given the poor air quality in so many places around the world, you could imagine that developing a low-cost, low-side-effect therapeutic to restore pulmonary macrophage function may be an important tool to combat increasing rates of lung disease,” Dr. Soloff said.

Next, the team will examine microplastic exposure in lung tissues from patients, with a long-term goal of establishing biomarkers for lung disease and lung cancer risk that could be used to trigger early screening or intervention.

 

###

 

VIEW ABSTRACT

You may also be interested in these abstracts.

 

A turning point in medicine: phage therapy moves from promise to practice



Berlin to host groundbreaking international conference targeting the clinical future of bacteriophages



Mitochondria-Microbiota Task Force

A Turning Point in Medicine: Phage Therapy Moves from Promise to Practice 

image: 

A Turning Point in Medicine: Phage Therapy Moves from Promise to Practice

 

view more 

Credit: @ Phage Therapy 2025 Meeting





Berlin, Germany – As antibiotic resistance accelerates into a global crisis, phage therapy is emerging as one of the most promising—and urgent—solutions in modern medicine. From June 10–11, 2025, the international scientific and medical community will gather in Berlin for Targeting Phage Therapy 2025, the leading global event focused on translating phage research into clinical reality.

With the theme “From Bench to Bedside: Accelerating Clinical Applications of Phage Therapy”, this year’s program brings together global leaders across infectious diseases, oncology, microbiome science, regulatory affairs, and biotechnology.

Strategic Aim: Clinical Implementation of Phage Therapy

This year’s edition is strategically designed to fast-track the integration of phage-based therapeutics into routine clinical practice. Key sessions will explore:

  • Ongoing clinical trials in cystic fibrosis, melanoma, and burn infections
  • Engineered phages for cancer and personalized microbiome modulation
  • Innovative delivery systems, from inhaled phages to hydrogels and tablets
  • Legal and regulatory frameworks enabling real-world phage deployment
  • GMP manufacturing pipelines and market access strategies

“The field has matured. The science is here. Now, our focus is clear: scale up production, secure regulatory approval, and deliver precision phage therapies to the patients who need them,” says Prof. Marvin Edeas, Chairman of the Scientific Committee.

Highlights from the 2025 Program – Major Speakers Include:

"Keynote Speech – Phage Therapy 2030: Getting from here to there"

  • Robert T. Schooley – University of California, San Diego (USA)

"Bacteriophage Therapy: A Renaissance – From Military Medicine to Civilian Healthcare"

  • Christian Willy – Academic Hospital Bundeswehr Berlin (Germany)

"Complex Phage Communities Control Gut (im)balances and May Hold the Key to Restore Gut Biosis"

  • Dennis Sandris Nielsen – University of Copenhagen (Denmark)

"Inhaled Bacteriophage Therapy for Multidrug Resistant Pseudomonas Aeruginosa: Advances & Perspectives"

  • Gail L. Stanley – Yale University (USA)

"KlebPhaCol: Novel Gut Phage Order Associated with the Human Gut"

  • Franklin Nobrega – University of Southampton (United Kingdom)

"Optimizing the Phage-Bacteria Ratio in Phage Therapy: Metagenomic Insights into Microbial Balance and Dysbiosis"

  • Domenico Frezza – University of Roma Tor Vergata (Italy)

"Phage Defense Systems: Are they an Obstacle for Phage Therapy?"

  • Stan J.J. Brouns – Delft University of Technology (The Netherlands)

"Biocontrol of Phage Resistance in Pseudomonas Infections – Fitness Trade-Offs Between Phages and Antibiotic Sensitivity"

  • Jumpei Fujiki – Rakuno Gakuen University (Japan)

"Yersinia Phage Stories: Impact on Phage Therapy"

  • Mikael Skurnik – University of Helsinki (Finland)

"Targeting Tumors with Engineered Phages: A New Frontier in Precision Oncology"

  • Alberto Danielli – University of Bologna (Italy)

"Engineering Phages for Cancer Therapy: Insights into Immune Interactions and Targeting in Ex-Vivo and In-Vivo Models"

  • Alena Kaltenbrunner – University of Bologna (Italy)

"Endolysin B as a New Approach & Archetype in M. Tuberculosis Treatment"

  • Loris Rizzello – University of Milan (Italy)

"Ex vivo pig lung as a new Cystic Fibrosis model for the study of Pseudomonas aeruginosa biofilm infection and phage therapy application"

  • Marco Cafora – University of Milan (Italy)

"Translating Phage Therapy into the Clinic: Recent Accomplishments and Next Challenges"

  • Jeremy Barr – Monash University (Australia)

"Bacteriophage Therapy for Critical Infections Related to Cardiothoracic Surgery"

  • Christian Kühn – Hannover Medical School (Germany)

"Phage Therapy in Veterinary Medicine: Presentation of First Clinical Trial in Japan"

  • Hidetomo Iwano – Rakuno Gakuen University (Japan)

"Bacteriophages Applications in Broiler Farms: Strategies & Perspectives"

  • Sandra Sevilla-Navarro – Centro de Calidad Avícola y Alimentación Animal de la Comunidad Valenciana (Spain)

"Phage Therapy in Europe: Legal, Regulatory and Ethic Issues"

  • Barbara Brenner – Kanzlei BRENNER (Germany)

 

Among the companies who will attend the congress:

Jafral (Supporter)
Amazon
Apothekendienstleistungen 
Aptar Radolfzell GmbH
Centro de Calidad Avícola y Alimentación Animal de la Comunidad Valenciana

ArGe Teknoloji Sanayi ve Ticaret Anonim Åžirketi
FagoFarma
TiPHAGE
Grachtenhaus-Apotheke e.K.
German Collection of Microorganisms and Cell Cultures GmbH
Inteliphage

Kanzlei BRENNER
Komplementäre Tiermedizin GmbH
LABOKLIN GmbH & Co. KG
Laboklin Phage Center
Laboratorios Syva
MB Pharma
MicrobiotiX
Medios AG
Nordmark Pharma
Otsuka Pharmaceutical CO.
Phileo by Lesaffre
Phagos
Precise Health SA
PrecisionPhage
Poulpharm
Qiagen
Rime Bioinformatics
Salem Microbes

A Defining Moment for Antibacterial Innovation

As resistance to antibiotics continues to grow, phage therapy is moving from scientific promise to clinical necessity. With over 75 communications, live discussions, and poster sessions attendees from 27 countires, the event aims to chart the course for clinical access, regulatory harmonization, and global collaborations.

For media inquiries, interviews, or partnership opportunities, visit: www.phagetherapy-site.com

MEDIA KIT

Phage Therapy: The Hottest Frontier in Tomorrow’s Medicine

Targeting Phage Therapy 2025
June 10–11, 2025 – Berlin, Germany
Website: www.phagetherapy-site.com

MEDIA CONTACT

Email: contact@phagetherapy-site.com

EVENT OVERVIEW

  • Title: Targeting Phage Therapy 2025
  • Dates: June 10–11, 2025
  • Location: Berlin, Germany
  • Format: In-person Conference
  • Organized by: International Society of Microbiota (ISM)

Strategic Theme:

“From Bench to Bedside: Accelerating Clinical Applications of Phage Therapy”

EVENT HIGHLIGHTS

  • 75+ talks and presentations from global experts coming from 27 Countries
  • Real-world clinical trials in cystic fibrosis, burn wounds, and TB
  • Live GMP manufacturing and regulatory strategy sessions
  • Cross-sector focus: Human health, oncology, veterinary, agriculture
  • Legal, ethical and market access discussions with EU stakeholders

PRESS MATERIALS

  • High-resolution conference logo
    Poster & social media banners (JPEG/PNG)
  • Full program (PDF)
  • Press release
  • Interview coordination available upon request

SOCIAL MEDIA & TAGS

Hashtags:

#PhageTherapy2025 | #Microbiome | #FutureOfMedicine | #PrecisionInfectiousCare

LinkedIn: https://www.linkedin.com/showcase/phage-therapy-task-force/

QUOTES FOR MEDIA USE

“Phage therapy is no longer experimental—it’s strategic. This conference marks the inflection point where science becomes practice.”

— Prof. Marvin Edeas, Chair, Scientific Committee

SEE 
 https://plawiuk.blogspot.com/search?q=PHAGES
https://plawiuk.blogspot.com/search?q=PHAGE
 https://plawiuk.blogspot.com/search?q=BIOPHAGES




Wednesday, February 05, 2025

 

Phages love to kill bacteria. Could they be used as antibiotics?



University of California - San Francisco






Scientists are learning more about how an intriguing type of virus protects itself. Revealing its strategies could boost the fight against antibiotic resistance.

Phages are viruses that attack bacteria by injecting their DNA, then usurping bacterial machinery to reproduce. Eventually, they make so many copies of themselves that the bacteria burst.

By looking at this process in a unique type of virus called a jumbo phage, scientists hope to learn how to make new antibiotics that can address the growing crisis of resistance.

The jumbo phage has more than four times the DNA of an average phage. It uses this genetic material to create a restricted space inside bacteria where it can copy its DNA while surrounded by a protective shield made of protein.

Researchers at UC San Francisco have discovered that the shield works via a set of “secret handshakes.” They allow only a specific set of useful proteins to pass through.

The handshakes all involve a large, central protein. It has a shape that lets it use different parts of itself to screen and recognize different proteins and grant them passage.

“This isn’t what we expected to see at all,” said Joseph Bondy-Denomy, PhD, associate professor of microbiology and immunology at UC San Francisco and senior author of the study, which appears Feb. 5 in Nature.

“It’s a surprisingly complicated thing for a phage to be doing,” he said.

Secret handshakes

Jumbo phages belong to a group of viruses called bacteriophages, or phages for short, which were discovered more than a century ago. Initially, phages were seen as a way to treat bacterial infections, because they are harmless to humans and can kill specific bacteria while leaving others alone. 

Interest died away once antibiotic drugs were developed, but the urgency to find new ways of fighting antibiotic-resistant bacteria is sparking it once again.

Scientists first began working on jumbo phages in the early 1980s but it wasn’t until 2017 that researchers at UCSF and UC San Diego worked together to identify the flexible protein that makes up the shield. 

In 2020, Bondy-Denomy led a study showing that the protein shield protects the phage’s DNA from attacks by the bacteria’s defenses.

He and Claire Kokontis, BS, a graduate student, suspected this shield may give jumbo phages distinct advantages over regular phages when it comes to using these viruses against infections.

The researchers wanted to learn how the shield recognizes the useful proteins and gives them passage into the protected area. 

The secret, they discovered, was a group of proteins made by the phage that interact in an unexpected way. 

At the center was a phage protein Kokontis called Importer1, or Imp1. For proteins to be imported into the protected space, they had to interact with Imp1. 

The researchers also found an additional set of importer proteins that assist Imp1 in bringing outside proteins through the shield. 

The interaction between Imp1 and a protein outside the shield needs to be just right before the protein gets the go-ahead to enter the protected area. 

“It’s like a secret handshake between two friends,” said Bondy-Denomy. “The ones that have the right handshake get the OK, and the others are tossed out.”

To see exactly what those handshakes looked like, Kokontis mapped the surface of the Imp1 “hand” at the molecular level. 

The map revealed that each phage protein that is allowed into the protected area has its own unique way of interacting with the Imp1 hand – one protein touches a thumb, another a finger, another a different finger. 

This variety of combinations allows the group of importer proteins to recognize an array of handshakes. 

A new way of making antibiotics

The researchers did their work using Pseudomonas bacteria, which they chose because it is notorious for its resistance to most antibiotics. 

What they learned will help scientists improve on an old approach that was left behind once antibiotics had become standard. Called phage therapy, it involves fighting one infection with another. First a human gets infected by bacteria. Then the human uses a phage to kill the bacteria. 

But bacteria are quick to evolve new defenses. Once they have devised a way to get past the phage’s protective shield, they will kill the phages.  

Understanding exactly how the shield’s secret handshakes work will help scientists engineer phages that can withstand these evolutionary changes. 

Bondy-Denomy’s lab has already developed a CRISPR-based method to make the necessary genetic changes to this specific family of phage. 

Scientists can also employ that knowledge to engineer jumbo phages that produce drugs or fight cancers caused by bacterial infections.

“We’re just at the starting point of realizing all this potential,” Kokontis said. “By getting a handle on the basic science of how these phages work, we’re laying the groundwork to adapt them for fighting disease.”


Authors: Other authors of this study are Timothy Klein and Sukrit Silas of UCSF

Funding: This work was funded by the NIH (grants R01 AI171041 and R01 AI167412).

 

About UCSF: The University of California, San Francisco (UCSF) is exclusively focused on the health sciences and is dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. UCSF Health, which serves as UCSF's primary academic medical center, includes top-ranked specialty hospitals and other clinical programs, and has affiliations throughout the Bay Area. UCSF School of Medicine also has a regional campus in Fresno. Learn more at ucsf.edu, or see our Fact Sheet.

###

 

Follow UCSF
ucsf.edu | Facebook.com/ucsf YouTube.com/ucsf